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Florence, ItalyA B S T R A C TObjective: To develop and validate the Italian Health Search Morbid-
ity (HSM) Index to adjust health care costs in general practice.
Methods: The study population comprised 1,076,311 patients registered
in the Health Search CSD Longitudinal Patient Database between January
1, 2008, and December 31, 2010. We randomly selected 538,254 and
538,057 patients to form the development and validation cohorts, respec-
tively. To ensure model convergence, 5% of the aforementioned cohorts
were selected randomly to create development and validation samples.
The outcome was the total direct health care costs covered by the
national health system. Interaction between age and sex, chronic dis-
eases, and acute diseases were entered in a multilevel generalized linear
latent mixed model with random intercepts (province of residence and
general practitioner) to identify determinants associated with increased or
decreased costs. The estimated coefﬁcients were linearly combined toee front matter Copyright & 2015, International S
r Inc.
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ndence to: Francesco Lapi, PharmD, PhD, Health Se
orence, Italy.create the HSM Index for individual patients. The score was applied to the
validation sample, and measures of predictive accuracy, explained
variance, and the observed/predicted ratio were computed to evaluate
the model’s accuracy. Results: The mean yearly cost was €414.57 per
patient, and the HSM Index had a median value of 5.08 (25th–75th range
4.44–5.98). The HSM Index explained 50.17% of the variation in costs.
Concerning calibration, in 80% of the population, the margin of error in
the estimation of costs was around 10%. Conclusions: The HSM Index is a
reliable case-mix system that could be implemented in general practice
for costs adjustment. This tool should ensure fairer scrutiny of resource
use and allocation of budgets among general practitioners.
Keywords: case-mix, costs adjustment, health care costs, HSM Index.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The burden of chronic diseases continues to grow in Western
countries, where it accounts for almost 80% of total health care
costs. Therefore, several health care systems have focused on
controlling the growth in spending on health services while
ensuring access to appropriate care [1–4]. General practice repre-
sents the most relevant setting for a cost assessment because
general practitioners (GPs) constitute the primary access to
health services, and control the diagnosis, management, pre-
scribing, and referral of patients with chronic diseases. Previous
studies conducted in the primary care setting in the United States
reported mean yearly costs of $1376 to $2655 per patient [5–7]; in
Europe, Engstrom et al. [8] estimated the mean yearly costs to be
between 978 and 6525 SEK (€106–€709; exchange rate June 2001)
per patient, increasing the complexity of the Adjusted Clinical
Group (ACG) clusters.
Several studies reported high variability in health care costs
between GPs, which led their authors to speculate that healthservices were not being used appropriately and efﬁciently [9–13].
Current methods of funding primary care still relate payments to
patients’ age and sex, but do not take comorbidities into account.
Therefore, case-mix adjustment systems based on objective
criteria have been developed to assign ﬁxed budgets for GPs. In
the United States, John Hopkins University developed the ACG
system, which has been subsequently adopted by other coun-
tries. The ACG system is supported by several studies that found
68 disease clusters to be better predictors of health care expendi-
tures than individual diseases [14–16]. The Charlson index was
also demonstrated to be effective in predicting costs in primary
care [5], and 16 other multimorbidity classiﬁcation systems are
currently available [16].
Although the ACG seems to be the most valid method for
predicting patient or health service costs, it is a proprietary risk
adjustment system that tends to be not transparent, very expen-
sive, and difﬁcult to understand for the ﬁnal user [8,16,17]. In
addition, the 68 mutually exclusive ACG categories are not
speciﬁcally targeted at patients with chronic disease, and areociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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coexistent diseases [16,17]. The Charlson index [5] better incor-
porates longitudinal assessment of chronic comorbidity; how-
ever, it was originally developed to predict the longitudinal risk of
mortality, which is likely the reason why it showed poor perform-
ance when compared with other case-mix systems directly
conceived to predict costs [17].
Any predictive score should be based on models developed in
populations representative of the speciﬁc country and clinical
setting in which the tool will be used [16,17]. In Italy, the public
health care system funds GPs via capitation fees for those
patients assigned to GPs by local health authorities (LHAs).
Despite the relevance of case-mix to estimate health care costs,
however, many LHAs still allocate budgets only on the basis of
patients’ age and sex. Such a model misspeciﬁcation might lead
to nonhorizontal equity, in which patients in equal need would
not receive the same health care because of unequal allocation of
the resources [18,19]. Although some LHAs have adopted ACG or
other adjustment scores, they recalibrate the scores using admin-
istrative databases [20] that are unable to capture many of the
clinical entities that pertain speciﬁcally to the primary care
setting. In addition, these local data sources are not representa-
tive of the general population.
The aim of this study was therefore to use prospectively
registered, primary care data to develop and validate the Health
Search Morbidity (HSM) Index for adjusting health care costs in
Italian general practice.Methods
Data Source
We obtained information from the Health Search – Cegedim
Strategic Data (CSD) Longitudinal Patients Database (HSD), an
Italian general practice data source that comprises electronic
health care records of a group of more than 1000 GPs distributed
throughout Italy. GPs voluntarily agreed to collect patients’
information and to attend training courses for data entry. The
HSD contains patients’ demographic details, which are linked
with an encrypted code to clinical records (diagnoses, referrals,
and tests results), drug prescriptions (drug name, date of ﬁlled
prescription, and number of days’ supply), prevention records,
hospital admissions, and date of death. GPs have to associate
every clinical information (e.g., blood test and drug prescription)
to a speciﬁc diagnosis. Each record is linked to the related cost (in
euros) assigned by the Ministry of Health. Data within the HSD
are coded using internationally recognized codes, such as the
International Classiﬁcation of Diseases, Ninth Revision, Clinical Mod-
iﬁcation for medical diagnoses and the Anatomical Therapeutic
Chemical classiﬁcation system for drugs. The validity of the HSD
data for conducting epidemiological research has been conﬁrmed
elsewhere [21–28].
To be considered for participation in epidemiological studies,
GPs are required to meet standard quality criteria pertaining to
the levels of coding, prevalence of well-known diseases, mortality
rates, and years of recording [29]. When this study was initiated,
700 GPs homogeneously distributed across all areas of Italy,
covering a patient population of 1,163,855 individuals, met the
standard quality criteria and were included in the study.Study Population
The study cohort comprised patients aged 15 years and older
drawn from the HSD during the 3 years between January 1, 2008,
and December 31, 2010. To be considered eligible, patients wererequired to have 3 years of complete data in their medical
records.
Outcome Deﬁnition
Our outcome was the total mean cost per year (in euros),
comprising ambulatory visits, specialist referrals, laboratory and
other diagnostic tests, and drug prescriptions covered by the
national health system.
Costs were assigned by the Ministry of Health according to
ofﬁcial national formularies, and were recorded prospectively. A
similar approach was adopted by other public health systems to
calculate the total costs speciﬁcally related to primary care [17].
Costs’ Determinants
To assess the costs associated with different comorbidities, we
examined the effect of several diseases in addition to the patient’s
age and sex. Each diagnosis was therefore deﬁned according to a
time frame that was suitable to estimate its cost-related burden.
To be considered as suffering from a chronic disease, patients
were required to be diagnosed at least once until June 30, 2009
(i.e., 18-month period) with one or more of the following: benign
neoplasia, HIV/AIDS, lymphoma, nonmetastatic or metastatic
carcinoma, thyroid disorders, type 2 and type 1 diabetes with or
without complications, dyslipidemia, hypertension with or with-
out complications, coronary ischemic diseases, arrhythmias,
cardiac valve diseases, atrial ﬁbrillation, heart failure, ischemic
stroke, hemorrhagic stroke, other ill-deﬁned cerebrovascular
disorders, peripheral vascular diseases, anemia, ocular disorders,
psychosis, psychotic-related mood disorders, personality disor-
ders, dementia, depression, Parkinson’s disease, neurotic dis-
eases, other neurological disorders, asthma, chronic obstructive
pulmonary disease, other chronic pulmonary diseases, gastro-
esophageal reﬂux disorder, peptic ulcer, abdominal hernias,
chronic liver diseases, chronic kidney diseases, psoriasis, pros-
tate diseases, osteoarthritis, rheumatoid arthritis, osteoporosis or
osteoporosis-related fractures, back disorders, migraine/head-
ache, disorders of veins and/or lymphatic vessels, dermatitis,
nutritional deﬁcits, electrolytic disorders, coagulation disorders,
paralysis, polyneuropathies, and cholelithiasis.
To be considered as suffering from an acute disease, patients
were required to be diagnosed at least once within a 12-month
period over the 3 years studied with one or more of the following:
Herpes zoster/simplex infections, mycoses, cystitis or other urinary
tract infections, menstrual or menopausal-related disorders,
gastrointestinal disorders, noninfective enteritis, acute respira-
tory infections, allergic rhinitis, inﬂuenza, pneumonia, dental
disorders, and otitis.
Data Analysis
The cohort was randomly divided into two cohorts, each con-
taining approximately 50% of the patients; these were referred to
as the development and validation cohorts. Given that the
“Gllamm” module of Stata (version 11.0, STATA Corp., College
Station, TX) is extremely inefﬁcient for numerical computation of
the log-likelihood for large-scale data sets and models with high-
order random effects [30], we randomly selected two further
samples, each containing 5% of the patients, to achieve models’
convergence; these two samples were referred to as the develop-
ment and validation samples. We reported descriptive statistics
for continuous (mean  SD) and categorical values (%).
The association between demographic characteristics and
comorbidities with health care costs was examined in the devel-
opment sample. Namely, model speciﬁcation was chosen on
clinical bases assuming that all the aforementioned candidate
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entered all candidate determinants in the model.
We used a multilevel generalized linear latent mixed model
(using the Gllamm module of Stata), including interaction between
age and sex, with province of patient’s residence and GP as random
intercepts (model 1). A gamma-binomial distribution was adopted
for the response variable. This analytic approach, which accounts
for the hierarchical structure of the data, was supported by recent
literature [31] and, in our data, by testing random effects with the
likelihood ratio test (chi-square ¼ 360.13; P o 0.001). We also
estimated three other models: a model with region of patient’s
residence as random intercept (model 2); a model without inter-
action between age and sex (model 3); and a model with cubic
fractional polynomial transformation of age (model 4).
In the development sample, we evaluated the model ﬁtting by
calculating Akaike information criterion (AIC) and Bayesian
information criterion (BIC). We therefore selected the model with
the lowest values of AIC and BIC. In the validation sample, we
evaluated the predictive accuracy of each model by calculating
mean squared error prediction (MSEP), bias, mean relative
squared error (MRSE), and mean absolute prediction error (MAPE).
The lowest values of these measures indicate the highest pre-
dictive accuracy [32,33].
Each determinant was assigned a regression b coefﬁcient
estimated in the models, and a patient-speciﬁc score was calcu-
lated in the development sample through the linear combination
of individual coefﬁcients. For all models, the HSM Index score
was reported as a median value with 25th and 75th percentile
and categorized in deciles. We also evaluated the accuracy of the
HSM Index (in deciles) for 1-year costs in the validation sample by
calculating the explained variance (R2) as a performance measure
and the ratio between expected and predicted costs as a calibra-
tion measure (a ratio of 1 indicates perfect calibration) [34].
We performed a sensitivity analysis to verify the robustness of
the results. We evaluated the impact of the inclusion of patients
with null costs [31,35,36]. We therefore estimated two further
models, with province (model 5) or region (model 6) as cluster and
gamma distribution for response variable, excluding patients
with null costs. AIC, BIC, bias, MSEP, MRSE, MAPE, R2, and
predicted/observed ratios were also calculated for these models.Results
Overall, 1,076,311 patients met the inclusion criteria, of whom
538,254 (285,346 women, 53.01%) and 538,057 (284,577 women,
52.89%) constituted the development cohort and the validation
cohort, respectively. Therefore, 26,889 and 26,903 patients were
randomly assigned to the 5% development and validation sam-
ples, respectively.
The mean yearly cost per patient was €414.57 (for patients
with non-null costs), and there was no substantial difference
between development and validation cohorts in terms of
disease prevalence. No substantial difference was also
observed for patients with null costs, whereas the prevalence
of chronic and acute illnesses was expectedly lower among
patients with null cost than among those with cost (Table 1).
Total yearly costs were higher among women than among
men; these increased with age, and were slightly higher for
patients with chronic diseases. Most of the cost was attribut-
able to metastatic and nonmetastatic carcinoma, type 1 dia-
betes, type 2 diabetes with complications, Parkinson’s disease,
hypertension with complications, coronary ischemic disease,
heart failure, ischemic stroke and other cerebrovascular dis-
orders, peripheral vascular diseases, chronic kidney diseases,
chronic obstructive pulmonary disease, other lung disorders,
and polyneuropathies; the mean costs of these diseasesexceeded €1000 per patient per year. The features of patients
selected in the 5% development sample were consistent with
those measured for the cohorts (Table 2).
Table 3 depicts the measures of model ﬁtting and predictive
accuracy for each estimated model. Model 1 and model 2 show
lower values of AIC and BIC. Although model 1 and model 2 were
almost equivalent, we opted for model 1 as the primary model
because the LHA with which a patient (and his or her GP) is
registered generally coincides with the province of residence,
several decisions on public health are made at this level [37,38],
and prediction of random intercept performs better with small
cluster sizes [39]. However, given that some decisions on public
health assistance are made at the region level [40,41], we
presented the results for both models.
Concerning predictive accuracy, bias, MSEP, MRSE, and MAPE
were lower for model 1 and model 2 than for model 3 and model
4. The HSM Index obtained with model 1 explained 50.17% of the
variation compared with only 26.23% explained by the model
including only age and sex.
The ratio of predicted to observed costs indicated a good
calibration for model 1, except for overprediction in the two
lowest deciles, wherein predicted costs were 67% and 26% greater
than observed costs. The results were almost identical across
models. The overprediction in the two lowest deciles was some-
what higher using region as cluster. In 80% of the population, the
margin of error in cost prediction was around 10% (Table 4).
Table 5 depicts the coefﬁcients calculated in the development
cohort using model 1. Each variable constituted an additional
cost to a patient’s health care. Among chronic disorders, other
neurologic disorders, type 1 diabetes, psychosis, type 2 diabetes
with complications, nonmetastatic carcinoma, and female infer-
tility had the greatest impact on the cost estimation, whereas
allergic rhinitis, gastroduodenitis, menstrual or menopausal dis-
orders, Herpes zoster/simplex infections, noninfective enteric col-
itis, cystitis, and respiratory infections were the most relevant for
acute diseases. Congestive heart failure, other ill-related cerebro-
vascular disorders, electrolytic disequilibrium, and hemorrhagic
stroke showed a decrease in costs, but the related P values were
extremely high (40.20). Overall, the HSM Index obtained with
model 1 has a median value of 5.08 (25th–75th range 4.44–5.98).
Figure 1 depicts unadjusted and adjusted health care costs
stratiﬁed by region. There was difference across Italian regions in
terms of unadjusted costs, and the HSM Index reduced the
burden of diseases in every region with the exception of Pie-
monte/Valle d’Aosta, Sardinia, Trentino Alto Adige/Friuli Venezia
Giulia, Veneto, and Emilia Romagna.
In the sensitivity analysis, when we excluded patients with
null costs and considered province of residence as cluster, the
multivariable model showed a predictive accuracy roughly con-
sistent with that of the primary model, and it explained 49.72% of
the costs compared with only 26.23% using the model with only
age and sex. With region as cluster, the multivariable model had
similar predictive accuracy and explained 49.71% of the variation
in costs (see Appendix Table 1 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2015.05.004). Concerning calibra-
tion, predicted/observed ratios still overestimated costs in the
ﬁrst two deciles, whereas the margin of error of cost prediction
was around 10% for the other deciles (see Appendix Table 2 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2015.05.004).Discussion
To our knowledge, this is the ﬁrst study to develop and validate a
case-mix index based on selected chronic and acute diseases
derived from a general practice database. In addition, this is the
Table 1 – Demographic, clinical features, and unadjusted health care cost in the development and validation cohorts.
Demographic and clinical
variable
Development cohort Validation cohort
Patients with cost 40 Patients with
null cost
Patients with cost 40 Patients with
null cost
N % of
patients
Unadjusted yearly
cost, mean  SD
N % of
patients
N % of
patients
Unadjusted yearly
cost, mean  SD
N % of
patients
Sex
Male 196,837 45.79 400.49  1071.14 56,071 51.71 197,546 45.98 401.12  1,286.49 55,934 51.59
Female 232,986 54.21 426.13  600.64 52,360 48.29 232,091 54.02 426.36  599.72 52,486 48.41
Age (y)
15–34 97,718 22.73 146.65  497.47 31,433 28.99 98,164 22.85 148.34  1,067.72 31,466 29.02
35–64 214,868 49.99 333.65  942.6 56,308 51.93 214,016 49.81 333.56  953.53 56,441 52.06
Z65 117,237 27.28 785.5  774.49 20,690 19.08 117,457 27.34 785.35  822.64 20,513 18.92
Chronic diseases 371,885 86.52 462.17  899.11* 37,251 34.35 371,649 86.50 462.32  1,035.53 37,295 34.40
Dorsopathies 169,349 39.40 509.53  912.86 10,160 9.37 168,941 39.32 512.45  1,095.86 10,222 9.43
Hypertension without
complications
124,935 29.07 767.82  754.2 7,512 6.93 125,312 29.17 768.19  808.45 7,443 6.86
Ocular disorders 115,234 26.81 603.3  736.79 6,500 5.99 115,440 26.87 601  780.91 6,291 5.80
Osteoarthritis 84,200 19.59 747.68  770.48 4,481 4.13 84,252 19.61 745.07  739.81 4,480 4.13
Diseases of veins and
lymphatic vessels
84,194 19.59 592.15  732.01 4,537 4.18 84,530 1.43 595.60  727.10 4,517 4.17
Dyslipidemia 63,269 14.72 767.18  765.16 2,757 2.54 62,676 14.59 760.44  774.21 2,682 2.47
Dermatitis 54,829 12.76 526.11  831.15 2,841 2.62 54,810 12.76 535.96  1,515.07 2,971 2.74
Thyroid disorders 52,362 12.18 646.57  742.33 2,478 2.29 52,153 12.14 654.5  754.54 2,577 2.38
Depression 51,459 11.97 685.66  789.23 3,171 2.92 51,071 11.89 684.07  761.4 3,184 2.94
Osteoporosis and related
fractures
50,326 11.71 767.59  813.1 2,773 2.56 50,469 11.75 765.7  805.8 2,805 2.59
GERD 47,418 11.03 702.07  786.52 2,102 1.94 47,273 11.00 699.82  768.21 2,153 1.99
Migraine/headache 42,424 9.87 442.3  595.56 2,668 2.46 42,225 9.83 441.48  621.45 2,633 2.43
Anemia 41,095 9.56 562.06  824.55 2,704 2.49 40,999 9.54 565.17  786.19 2,708 2.50
Neurotic diseases 40,480 9.42 568.92  704.93 2,240 2.07 40,412 9.41 574.33  850.64 2,201 2.03
Benign tumors 40,415 9.40 592.72  738.37 1,707 1.57 40,503 9.43 598.33  728.96 1,675 1.54
Other chronic pulmonary
diseases
35,485 8.26 654.3  762.24 1,810 1.67 35,371 8.23 663.09  900.57 1,817 1.68
Prostate diseases 34,576 8.04 817.79  830.42 1,612 1.49 34,513 8.03 812.92  831.2 1,489 1.37
Type 2 diabetes without
complications
33,061 7.69 901.35  848.33 2,170 2.00 33,411 7.78 900.68  848.32 2,089 1.93
Abdominal hernias 29,034 6.75 673.51  1,026.84 1,583 1.46 28,946 6.74 670.81  963.06 1,566 1.44
Arrhythmias 27,293 6.35 657.26  752.92 1,322 1.22 27,436 6.39 669.03  2,054.84 1,358 1.25
Asthma 27,021 6.29 540.96  682.65 1,827 1.68 27,051 6.30 536.84  667.25 1,889 1.74
Obesity 25,956 6.04 597.59 (712.2) 1,423 1.31 25,939 6.04 601.9  718.35 1,401 1.29
Chronic liver diseases 23,804 5.54 758.22  2,071.38 1,648 1.52 23,733 5.52 741.26  953.28 1,580 1.46
Cholelithiasis 22,338 5.20 748.71  881.42 1,146 1.06 22,526 5.24 740  846.48 1,162 1.07
Nonmetastatic carcinomas 21,465 4.99 1,075  1,166.23 1,714 1.58 21,926 5.10 1,079.18  1344.74 1,694 1.56
Coronary ischemic
diseases
20,561 4.78 1,176.04  889.67 1,363 1.26 20,665 4.81 1,165.79  863.58 1,327 1.22
Psoriasis 16,610 3.86 543.61  745.29 967 0.89 16,596 3.86 541.75  781.41 975 0.90
continued on next page
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Table 1 – continued
Demographic and clinical
variable
Development cohort Validation cohort
Patients with cost 40 Patients with
null cost
Patients with cost 40 Patients with
null cost
N % of
patients
Unadjusted yearly
cost, mean  SD
N % of
patients
N % of
patients
Unadjusted yearly
cost, mean  SD
N % of
patients
Peptic ulcer 14,318 3.33 750.43  814.01 1,088 1.00 14,449 3.36 742.16  785.38 1,123 1.04
COPD 14,242 3.31 1,086.46  934.92 809 0.75 14,220 3.31 1083.3  974.1 831 0.77
Ischemic stroke 14,117 3.28 1,051.26  860.36 788 0.73 13,818 3.22 1,057.09  838.87 776 0.72
Cardiac valve diseases 11,885 2.77 751.05  791.21 616 0.57 11,940 2.78 766.31  1116.94 645 0.59
Peripheral vascular
diseases
11,640 2.71 1,045.94  909.8 479 0.44 11,709 2.73 1,041.39  877.22 489 0.45
Atrial ﬁbrillation 10,401 2.42 997.87  830.72 643 0.59 10,257 2.39 997.02  792.58 639 0.59
Rheumatoid arthritis 9,040 2.10 834.31  871.09 446 0.41 8,993 2.09 838.08  880.34 420 0.39
Chronic kidney disease 8,231 1.91 1,281.4  1213.67 462 0.43 8,237 1.92 1,251.08  1146.15 470 0.43
Dementia 8,147 1.90 925.81  877.24 756 0.70 8,342 1.94 918.97  798.16 829 0.76
Personality disorders 8,017 1.87 717.4  769.62 337 0.31 8,110 1.89 723.76  829.45 339 0.31
Hypertension with
complications
7,774 1.81 1,100.13  899.21 450 0.42 7,868 1.83 1,082.89  897.77 476 0.44
Type 2 diabetes with
complications
6,729 1.57 1,467.17  1,069.59 174 0.16 6,689 1.56 1,437.89  1,020.55 227 0.21
Other neurologic
disturbances
6,414 1.49 824.71  1,086.39 532 0.49 6,479 1.51 809.49  1,093.96 546 0.50
Other and ill-deﬁned
cerebrovascular
disorders
6,234 1.45 1,011.38  801.21 411 0.38 6,163 1.43 1,011.79  796.76 456 0.42
Congestive heart failure 4,885 1.14 1,200.14  1,015.72 430 0.40 4,821 1.12 1,151.85  926.5 419 0.39
Nutritional deﬁcit 3,743 0.87 531.76  741.95 185 0.17 3,778 0.88 521.75  710.75 202 0.19
Psychosis 3,292 0.77 782.7  896.52 357 0.33 3,381 0.79 760.24  896.76 347 0.32
Lymphomas 3,094 0.72 801.61  1,055.83 262 0.24 3,109 0.72 833.42  1,061.38 266 0.25
Coagulation diseases 3,026 0.70 912.09  6,919.93 149 0.14 2,970 0.69 985.62  9,094.15 134 0.12
Female infertility 2,574 0.60 499.22  804.9 177 0.16 2,469 0.57 490.11  728.92 159 0.15
Parkinson’s disease 2,204 0.51 1,462.98  1,244.52 242 0.22 2,156 0.50 1,462.57  1,250.53 226 0.21
Electrolytic disequilibrium 2,168 0.50 965.44  980.02 77 0.07 2,206 0.51 950.95 2,321.07 92 0.08
Polyneuropathies 1,994 0.46 1,370.42  1,163.85 74 0.07 1,986 0.46 1,427.95  1,200.52 90 0.08
Lung disorders 1,293 0.30 1,110.37  918.64 118 0.11 1,305 0.30 1,101.08  929.4 123 0.11
Psychotic disorders 1,019 0.24 861.2  1,084.88 82 0.08 952 0.22 899.59  908.45 85 0.08
Type 1 diabetes 882 0.21 1,345.33  1,077.66 58 0.05 920 0.21 1,347.42  974.82 59 0.05
Hemorrhagic stroke 851 0.20 831.88  743.39 90 0.08 834 0.19 894.4  828.82 59 0.05
Paralysis 677 0.16 670.91  761.64 51 0.05 657 0.15 686.85  815.84 59 0.05
Metastatic carcinomas 358 0.08 1,833.71  1,690.41 44 0.04 408 0.09 1,742.44  1,770.58 53 0.05
HIV/AIDS 313 0.07 665.61  1329.27 58 0.05 313 0.07 490.02  888.49 64 0.06
Acute diseases 240,044 55.84 454.81  698.22* 1,801 1.66 240,432 55.96 449.08  1,175.53 1,789 1.65
Acute respiratory
infections
121,311 28.22 410.46  703.33 1,000 0.92 120,886 28.14 412.8  1,499.5 989 0.91
Dental diseases 40,420 9.40 494.68  866.86 117 0.11 40,307 9.38 503.66  1,944.36 128 0.12
Respiratory symptoms 40,068 9.32 590.84  920.07 96 0.09 39,916 9.29 582.96  718.39 110 0.10
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Table 1 – continued
Demographic and clinical
variable
Development cohort Validation cohort
Patients with cost 40 Patients with
null cost
Patients with cost 40 Patients with
null cost
N % of
patients
Unadjusted yearly
cost, mean  SD
N % of
patients
N % of
patients
Unadjusted yearly
cost, mean  SD
N % of
patients
Cystitis 29,967 6.97 581.04  748.2 38 0.04 29,815 6.94 586.34  2,170.07 35 0.03
Mycosis 24,650 5.73 515.09  720.23 38 0.04 24,603 5.73 526.89  2,153.25 41 0.04
Acute otitis media 23,498 5.47 483.79  693.32 89 0.08 23,388 5.44 483.49  656.11 93 0.09
Gastroduodenitis 22,199 5.16 565.67  1045.19 56 0.05 22,155 5.16 564.83  720.15 70 0.06
Menstrual or menopausal
disorders
17,797 4.14 397.69  490.95 48 0.04 17,864 4.16 390.56  477.67 56 0.05
Enteric colitis 13,280 3.09 473.74  1,218.72 176 0.16 13,215 3.08 447.16  656.47 127 0.12
Inﬂuenza and pneumonia 12,937 3.01 495.99  753.31 193 0.18 12,730 2.96 500.18  732.82 189 0.17
Urinary tract infections 11,267 2.62 686.31  889.43 14 0.01 11,492 2.67 675.75  765.46 9 0.01
Herpes (zoster/simplex) 10,543 2.45 601.59  753.76 25 0.02 10,552 2.46 612.26  767.35 23 0.02
Allergic rhinitis 7,850 1.83 366.93  542.39 41 0.04 7,722 1.80 379.55  674.5 51 0.05
Other diseases 39,9360 92.91 426.59  869.04 53,086 48.96 399,397 92.96 426.57  1,003.64 53,258 49.12
Note. Acute diseases also comprise syndromes, symptoms, and infections.
COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reﬂux disease.
* Patients with at least one condition.
Table 2 – Demographic and clinical features and unadjusted health care costs in the development cohort and the 5% development sample.
Demographic and clinical
variable
Development cohort 5% development sample
Patients with cost Patients with
null cost
Patients with cost Patients with
null cost
N % of
patients
Unadjusted yearly
cost, mean  SD
N % of
patients
N % of
patients
Unadjusted yearly
cost, mean  SD
N % of
patients
Sex
Male 196,837 45.79 400.49  1071.14 56,071 51.71 9,738 45.57 385.81  604.52 2,825 51.17
Female 232,986 54.21 426.13  600.64 52,360 48.29 11,630 54.43 421.87  557.93 2,696 48.83
Age (y)
15–34 97,718 22.73 146.65  497.47 31,433 28.99 4,945 23.14 137.4  209.38 1,585 28.71
35–64 214,868 49.99 333.65  942.6 56,308 51.93 10,781 50.45 326.64  501.72 2,865 51.89
Z65 117,237 27.28 785.5  774.49 20,690 19.08 5,642 26.40 790.95  728.53 1,071 19.40
Chronic diseases 371,885 86.52 462.17  899.11* 37,251 34.35 18,458 86.38 452.97  607.25* 1,930 34.95
Dorsopathies 169,349 39.40 509.53  912.86 10,160 9.37 8,396 39.29 502.85  629.89 501 9.07
Hypertension without
complications
124,935 29.07 767.82  754.2 7,512 6.93 6,182 28.93 758  692.74 395 7.15
Ocular disorders 115,234 26.81 603.3  736.79 6,500 5.99 5,728 26.81 604.65  691.63 343 6.21
Osteoarthritis 84,200 19.59 747.68  770.48 4,481 4.13 4,174 19.53 739  718.54 260 4.71
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Table 2 – continued
Demographic and clinical
variable
Development cohort 5% development sample
Patients with cost Patients with
null cost
Patients with cost Patients with
null cost
N % of
patients
Unadjusted yearly
cost, mean  SD
N % of
patients
N % of
patients
Unadjusted yearly
cost, mean  SD
N % of
patients
Diseases of veins and
lymphatic vessels
84,194 19.59 592.15  732.01 4,537 4.18 4,169 19.51 601.15  726.46 241 4.37
Dyslipidemia 63,269 14.72 767.18  765.16 2,757 2.54 3,107 14.54 750.32  711.62 135 2.45
Dermatitis 54,829 12.76 526.11  831.15 2,841 2.62 2,724 12.75 549.27  678.12 155 2.81
Thyroid disorders 52,362 12.18 646.57  742.33 2,478 2.29 2,559 11.98 640.08  667.2 137 2.48
Depression 51,459 11.97 685.66  789.23 3,171 2.92 2,515 11.77 693.1  763.74 157 2.84
Osteoporosis and related
fractures
50,326 11.71 767.59  813.1 2,773 2.56 2,487 11.64 767.43  767.27 144 2.61
GERD 47,418 11.03 702.07  786.52 2,102 1.94 2,338 10.94 743.46  831.99 98 1.78
Migraine/headache 42,424 9.87 442.3  595.56 2,668 2.46 2,169 10.15 433.41  539.28 130 2.35
Anemia 41,095 9.56 562.06  824.55 2,704 2.49 2,007 9.39 553.16  719.67 140 2.54
Neurotic diseases 40,480 9.42 568.92  704.93 2,240 2.07 1,996 9.34 564.31  667.43 4 0.07
Benign tumors 40,415 9.40 592.72  738.37 1,707 1.57 2,063 9.65 603.61  699.13 92 1.67
Other chronic pulmonary
diseases
35,485 8.26 654.3  762.24 1,810 1.67 1,717 8.04 636.2  745.11 91 1.65
Prostate diseases 34,576 8.04 817.79  830.42 1,612 1.49 1,701 7.96 805.42  775.88 84 1.52
Type 2 diabetes without
complications
33,061 7.69 901.35  848.33 2,170 2.00 1,600 7.49 890.25  776.57 119 2.16
Abdominal hernias 29,034 6.75 673.51  1026.84 1,583 1.46 1,477 6.91 654.5  693.59 75 1.36
Arrhythmias 27,293 6.35 657.26  752.92 1,322 1.22 1,409 6.59 682.84  749.9 63 1.14
Asthma 27,021 6.29 540.96  682.65 1,827 1.68 1,338 6.26 526.56  647.93 102 1.85
Obesity 25,956 6.04 597.59  712.2 1,423 1.31 1,316 6.16 581.08  734.34 70 1.27
Chronic liver diseases 23,804 5.54 758.22  2,071.38 1,648 1.52 1,155 5.41 762.87  903.86 94 1.70
Cholelithiasis 22,338 5.20 748.71  881.42 1,146 1.06 1,135 5.31 737.44  759.22 69 1.25
Nonmetastatic carcinomas 21,465 4.99 1,075  1,166.23 1,714 1.58 1,037 4.85 1,048.11  1,044.07 89 1.61
Coronary ischemic diseases 20,561 4.78 1,176.04  889.67 1,363 1.26 1,011 4.73 1,192.97  839.13 72 1.30
Psoriasis 16,610 3.86 543.61  745.29 967 0.89 829 3.88 546.89  664.66 53 0.96
Peptic ulcer 14,318 3.33 750.43  814.01 1,088 1.00 678 3.17 672.44  637.29 58 1.05
COPD 14,242 3.31 1,086.46  934.92 809 0.75 711 3.33 1,094.09  981.52 38 0.69
Ischemic stroke 14,117 3.28 1,051.26  860.36 788 0.73 711 3.33 1,067.46  808.24 44 0.80
Cardiac valve diseases 11,885 2.77 751.05  791.21 616 0.57 614 2.87 742.91  660.45 25 0.45
Peripheral vascular diseases 11,640 2.71 1,045.94  909.8 479 0.44 561 2.63 1,018.34  767.09 21 0.38
Atrial ﬁbrillation 10,401 2.42 997.87  830.72 643 0.59 522 2.44 1,036.15  863.66 31 0.56
Rheumatoid arthritis 9,040 2.10 834.31  871.09 446 0.41 422 1.97 865.89  863.49 28 0.51
Chronic kidney disease 8,231 1.91 1281.4  1213.67 462 0.43 408 1.91 1,197.42  1,050.9 18 0.33
Dementia 8,147 1.90 925.81  877.24 756 0.70 378 1.77 996.7  958.85 35 0.63
Personality disorders 8,017 1.87 717.4  769.62 337 0.31 373 1.75 706.52  764.02 18 0.33
Hypertension with
complications
7,774 1.81 1,100.13  899.21 450 0.42 372 1.74 1,121.65  804.65 28 0.51
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Table 2 – continued
Demographic and clinical
variable
Development cohort 5% development sample
Patients with cost Patients with
null cost
Patients with cost Patients with
null cost
N % of
patients
Unadjusted yearly
cost, mean  SD
N % of
patients
N % of
patients
Unadjusted yearly
cost, mean  SD
N % of
patients
Type 2 diabetes with
complications
6,729 1.57 1,467.17  1,069.59 174 0.16 344 1.61 1,417.94  835.37 10 0.18
Other neurologic
disturbances
6,414 1.49 824.71  1,086.39 532 0.49 328 1.54 823.46  992.45 19 0.34
Other and ill-deﬁned
cerebrovascular disorders
6,234 1.45 1,011.38  801.21 411 0.38 303 1.42 948.58  693.61 27 0.49
Congestive heart failure 4,885 1.14 1,200.14  1,015.72 430 0.40 280 1.31 1,098.43  790.35 22 0.40
Psychosis 3,292 0.77 782.7  896.52 357 0.33 171 0.80 768.68  915.76 20 0.36
Lymphomas 3,094 0.72 801.61  1,055.83 262 0.24 170 0.80 892.66  1,146.09 10 0.18
Nutritional deﬁcit 3,743 0.87 531.76  741.95 185 0.17 167 0.78 577.02  626.99 10 0.18
Coagulation diseases 3,026 0.70 912.09  6919.93 149 0.14 148 0.69 570.51  681.81 6 0.11
Female infertility 2,574 0.60 499.22  804.9 177 0.16 112 0.52 388.2  491.71 4 0.07
Parkinson’s disease 2,204 0.51 1,462.98  1,244.52 242 0.22 118 0.55 1,424.54  1,135.22 11 0.20
Electrolytic disequilibrium 2,168 0.50 965.44  980.02 77 0.07 96 0.45 929.21  990.13 3 0.05
Polyneuropathies 1,994 0.46 1,370.42  1,163.85 74 0.07 96 0.45 1,224  970.19 3 0.05
Lung disorders 1,293 0.30 1,110.37  918.64 118 0.11 74 0.35 1,148.96  825.55 9 0.16
Psychotic disorders 1,019 0.24 861.2  1,084.88 82 0.08 48 0.22 793  633.15 115 2.08
Type 1 diabetes 882 0.21 1,345.33  1077.66 58 0.05 46 0.22 1,350.92  899.93 2 0.04
Hemorrhagic stroke 851 0.20 831.88  743.39 90 0.08 54 0.25 667.88  544.55 6 0.11
Paralysis 677 0.16 670.91  761.64 51 0.05 29 0.14 569.92  712.96 2 0.04
Metastatic carcinomas 358 0.08 1,833.71  1,690.41 44 0.04 25 0.12 1,668.86  1,830.69 2 0.04
HIV/AIDS 313 0.07 665.61  1,329.27 58 0.05 19 0.09 493.21  531.71 5 0.09
Acute diseases 240,044 55.84 454.81  698.22* 1,801 1.66 12,045 56.37 445.71  625.4* 100 1.81
Acute respiratory infections 121,311 28.22 410.46  703.33 1,000 0.92 6,032 28.23 401.57  600.12 48 0.87
Dental diseases 40,420 9.40 494.68  866.86 117 0.11 2,019 9.45 490.21  626.36 3 0.05
Respiratory symptoms 40,068 9.32 590.84  920.07 96 0.09 2,008 9.40 600.32  723.27 5 0.09
Cystitis 29,967 6.97 581.04  748.2 38 0.04 1,522 7.12 592.6  739.32 6 0.11
Mycosis 24,650 5.73 515.09  720.23 38 0.04 1,299 6.08 496.78  620.68 7 0.13
Acute otitis media 23,498 5.47 483.79  693.32 89 0.08 1,200 5.62 489.51  661.87 7 0.13
Gastroduodenitis 22,199 5.16 565.67  1,045.19 56 0.05 1,106 5.18 525.87  611.09 7 0.13
Menstrual or menopausal
disorders
17,797 4.14 397.69  490.95 48 0.04 868 4.06 390.18  436.6 3 0.05
Enteric colitis 13,280 3.09 473.74  1,218.72 176 0.16 641 3.00 438.63  607.18 9 0.16
Inﬂuenza and pneumonia 12,937 3.01 495.99  753.31 193 0.18 679 3.18 527.95  801.15 12 0.22
Urinary tract infections 11,267 2.62 686.31  889.43 14 0.01 570 2.67 684.21  788.58 0 0.00
Herpes (zoster/simplex) 10,543 2.45 601.59  753.76 25 0.02 522 2.44 660.23  764.38 1 0.02
Allergic rhinitis 7850 1.83 366.93  542.39 41 0.04 380 1.78 377.01  534.61 1 0.02
Other diseases 399,360 92.91 426.59  869.04 53,086 48.96 19,949 93.36 416.22  587.45 2,722 49.30
Note. Acute diseases also comprise syndromes, symptoms, and infections.
COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reﬂux disease.
* At least one condition.
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Table 3 – Multilevel generalized linear latent mixed model including interaction between age and sex, with
province (model 1) or region (model 2) of patient’s residence and general practitioners as random intercepts;
model without interaction (model 3) or with cubic fractional polynomial transformation of age (model 4), with
province of patient’s residence and general practitioners as random intercept.
Model Model ﬁtting* Predictive accuracy† Explained variance†
AIC BIC MSPE Bias MRSE MAPE R2 R2‡
Model 1 332,526.2 333,220.1 662,507.2 26.84 660.23 284.03 50.17 26.23
Model 2 332,362.9 333,065.6 646,112.7 25.89 655.25 283.64 50.16
Model 3 332,778.5 333,472.5 889,745.1 39.64 770.70 293.5 49.71
Model 4 327,638.3 328,331.3 727,986.7 29.38 693.78 282.76 50.51
AIC, Akaike information criterion; BIC, Bayesian information criterion; MAPE, mean absolute prediction error; MRSE, mean relative squared
error; MSEP, mean squared error prediction.
* Development sample.
† Validation sample.
‡ Model only with age and sex; gamma-binomial distribution is used for the response variable in all models.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 8 4 – 8 9 5892ﬁrst case-mix index being directly developed from the Italian
primary care data. The HSM Index showed good predictive
accuracy, performance, and calibration, and indicated that
comorbidity was pivotal in cost adjustment, in which it explained
50.17% of the variance. For almost all Italian regions, the HSM
Index lowered the burden of diseases. Overall, the results of the
sensitivity analysis were consistent with those obtained with the
primary model.
Other studies have developed comorbidity scores with which
to predict health care costs in general practice. These scores,
such as the ACG or Diagnostic Cost Groups, focused mainly on
clinical variables, including those that use data on previous
hospitalizations or ambulatory care to categorize patients
[14,16,42,43]. The ACG categorizes patients according to individ-
ual morbidity clusters as predictors of health care expenditures,
whereas the Diagnostic Cost Group is based on hierarchical
concurrent conditions that sum the predicted costs without
being limited to the single highest cost disease. These
approaches, however, do not treat comorbidity as a weighted
aggregate index that is applied longitudinally [5]. This is mainly
because such systems often use Diagnosis Related Groups
derived from hospitalization data, which are poorly able to
capture the longitudinal component of comorbidity. Further-
more, they are proprietary systems, which are not transparent
and difﬁcult to use. The ACG system has been demonstrated toTable 4 – Predicted/observed ratios for HSM-Index decile
term between age and sex, with province (model 1) or re
practitioners as random intercepts; model without intera
transformation of age (model 4), with province of patien
intercept (validation sample).
HSM-Index deciles Model 1* M
First 1.67
Second 1.26
Third 1.14
Fourth 1.07
Fifth 1.02
Sixth 0.99
Seventh 0.97
Eighth 0.97
Ninth 0.96
Tenth 0.93
* Including all variables in Table 2; gamma-binomial distribution is usedbe sensitive to the accuracy of classiﬁcation and coding of
diagnoses by GPs, thus introducing potential bias into the
estimates of practices’ morbidity scores [8]. Other case-mix
systems, such as that based on 17 Quality of Framework concepts
[44], have demonstrated better performance than ACG (R2 ¼ 0.31
vs. R2 ¼ 0.27) in the United Kingdom. This may be because the
ACG clusters were not originally intended to be applied to
patients with chronic diseases who make up one of the main
activities of GPs, and were developed in different (US) popula-
tions [17].
To overcome these issues, Charlson et al. [5] adapted the
Charlson comorbidity index to predict health care costs using a
longitudinal approach. Overall, this index explained 20.2% of the
variance; comorbidity explained 15.5% of the variance in costs
when added to the model with only age and sex [5]. Nevertheless,
the Charlson comorbidity index performed poorly when com-
pared with other simpler case-mix systems [17]. This is likely
because the score was primarily focused on prediction of mortal-
ity rather than costs of general practice.
In the present study, we attempted to improve on these
previous works. First, we developed an index that used both
chronic and acute conditions in an attempt to create a multi-
variable model with the highest predictive accuracy, highest
explained variance, and best calibration. Second, we developed
the HSM Index using prospectively acquired data, in which thes predicted using the model including the interaction
gion (model 2) of patient’s residence and general
ction (model 3) or with cubic fractional polynomial
t’s residence and general practitioners as random
odel 2* Model 3* Model 4*
1.67 1.68 1.67
1.26 1.26 1.26
1.14 1.14 1.14
1.07 1.07 1.07
1.02 1.02 1.02
0.99 0.99 0.99
0.97 0.97 0.98
0.97 0.97 0.97
0.96 0.96 0.96
0.93 0.93 0.93
for the response variable in all models.
Table 5 – Multivariable coefﬁcients of yearly health
care costs in the validation sample.
Variable Coefﬁcient
Chronic diseases
Other neurologic disorders 1.04
Type 1 diabetes 1.02
Psychosis 0.89
Type 2 diabetes with complications 0.82
Nonmetastatic carcinomas 0.81
Female infertility 0.80
Psychotic disorders 0.77
Parkinson’s disease 0.69
Type 2 diabetes without complications 0.66
Hypertension without complications 0.59
Lymphomas 0.53
Coronary ischemic diseases 0.52
Metastatic carcinomas 0.50
HIV/AIDS 0.43
Rheumatoid arthritis 0.42
Asthma 0.38
Paralysis 0.35
COPD 0.33
Chronic liver diseases 0.28
Dyslipidemia 0.28
GERD 0.27
Thyroid disorders 0.27
Cardiac valve diseases 0.27
Prostate diseases 0.26
Depression 0.26
Migraine/headache 0.22
Hypertension with complications 0.21
Psoriasis 0.20
Osteoporosis and related fractures 0.20
Coagulation diseases 0.19
Ischemic stroke 0.19
Dorsopathies 0.18
Arrhythmias 0.18
Dementia 0.16
Benign tumors 0.16
Neurotic diseases 0.16
Nutritional deﬁcit 0.16
Atrial ﬁbrillation 0.15
Abdominal hernias 0.15
Other chronic pulmonary diseases 0.13
Diseases of veins and lymphatic vessels 0.13
Polyneuropathies 0.12
Ocular disorders 0.12
Personality disorders 0.12
Lung disorders 0.12
Chronic kidney disease 0.11
Dermatitis 0.09
Anemia 0.09
Obesity 0.09
Peptic ulcer 0.08
Peripheral vascular diseases 0.06
Osteoarthritis 0.05
Cholelithiasis 0.05
Congestive heart failure –0.04
Electrolytic disequilibrium –0.05
Other and ill-deﬁned cerebrovascular disorders –0.06
Hemorrhagic stroke –0.06
Acute diseases
Allergic rhinitis 0.45
Gastroduodenitis 0.42
continued on next page
Table 5 – continued
Variable Coefﬁcient
Menstrual or menopausal disorders 0.39
Herpes (zoster/simplex) 0.34
Noninfective enteric colitis 0.33
Cystitis 0.32
Respiratory infections 0.32
Urinary tract infections 0.32
Respiratory symptoms 0.29
Dental diseases 0.27
Inﬂuenza and pneumonia 0.23
Otitis media 0.23
Mycosis 0.22
Other diseases 0.89
Note. Acute diseases also comprise syndromes, symptoms, and
infections.
COPD, chronic obstructive pulmonary disease; GERD, gastroeso-
phageal reﬂux disease.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 8 4 – 8 9 5 893health care costs were directly derived from a primary care
setting [12,13,17].
Third, given that the HSM Index provides the extent of
individual determinants, it might be simply implemented in
software for GPs’ self-auditing and public health authorities.
Interestingly, the coefﬁcients related to congestive heart fail-
ure, other ill-related cerebrovascular disorders, electrolytic
disequilibrium, and hemorrhagic stroke showed a decrease in
costs, albeit with high P values. This result might be explained
by the fact that these conditions refer to common syndromes,
such as electrolytic disequilibrium, that are less severe and
costly than other concurrent diseases, or diseases such as
congestive heart failure and other ill-related cerebrovascular
disorders and hemorrhagic stroke, which are mainly treated in
hospital without being directly followed by GP. Finally, in view
of the institutional differences across countries, we developed
the HSM Index using an Italian general practice database,
which represents the clinical setting in which this tool will be
eventually used [17]. In this regard, given the regional feder-
alism in Italy, we observed certain variation in costs across
regions. However, the HSM Index generally increased costs,
thus demonstrating that most of the GPs “spend” less than
what is observed.
As with other case-mix systems, the HSM Index has poten-
tial limitations. First, the fact that we were unable to include
hospitalization-related costs led to underestimation of the
outcome. Our index, however, was conceived for adjustment
purposes in a primary care setting based on the GPs-related
expenditure, and not to predict the total cost of a single
disease. In other words, given that the direct contribution of
the GP’s behavior to in-hospital costs is likely minimal and
the high accuracy of our multivariable model, we believe
that the HSM Index could be reliably adopted for cost adjust-
ment. Second, we did not have access to information on
patients’ race, disabilities, or socioeconomic status, which
can be signiﬁcant determinants of health care costs [45–47].
Socioeconomic status has been demonstrated to have a small
effect on model ﬁt [17], and it must be, along with race and
disabilities, above and beyond the factors already included in
the model.
In conclusion, the HSM Index showed good accuracy and its
use should be considered when examining cost variation among
GPs in Italy. This tool might be associated with other perform-
ance indicators to ensure a fairer scrutiny of resource use and
allocation of budgets among GPs.
Fig. 1 – Unadjusted (black points) and adjusted (gray points) health care costs by Italian region. Piemonte and Valle d’Aosta,
Basilicata and Calabria, and Trentino Alto Adige and FVG were grouped because they were formed by smaller samples. FVG,
Friuli Venezia Giulia.
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